Cutaneous adverse events

Enfortumab Vedotin-Induced Cutaneous Toxicity: A Marker of Improved Survival in Advanced Urothelial Carcinoma

Enfortumab vedotin (EV) therapy in advanced urothelial carcinoma is frequently associated with cutaneous adverse events (cAEs). These EV-induced skin toxicities correlate independently with improved progression-free and overall survival, ev